Article: Nicotinamide Riboside Enhances Brain Enzymes to Combat Alzheimer’s Pathology: Preclinical Findings

PrevNext
Alzheimer's Disease Metabolic Health Neurological Health Preclinical

Nicotinamide Riboside Enhances Brain Enzymes to Combat Alzheimer’s Pathology: Preclinical Findings

Synopsis

SIRT3 is a mitochondrial enzyme that improves cell function. Deleting SIRT3 causes brain mitochondrial problems and worsens Alzheimer's disease (AD) features in mice, including insulin resistance and amyloid plaque buildup. This study found that loss of SIRT3 lowers insulin-degrading enzyme (IDE) levels, which normally clears insulin and amyloid-beta peptides. A Western diet reduced IDE and SIRT3 levels in AD mice. Boosting SIRT3 with nicotinamide riboside increased IDE and another amyloid-clearing enzyme (neprilysin), while reducing an enzyme that produces amyloid (BACE1). This suggests SIRT3 helps protect against AD by regulating key enzymes involved in insulin and amyloid clearance.

Journal

Scientific Reports

Share

Read more

Liver Health

Nicotinamide Riboside Enhances Liver Regeneration: Preclinical Findings

SynopsisThe regenerative capacity of the liver is essential for recovery from surgical resection or injuries induced by trauma or toxins. During liver regeneration, the concentration of nicotinamid...

Read more
Liver Health

Nicotinamide Riboside Corrects Metabolic Imbalances and Mitochondrial Dysfunction in Citrin Deficiency: Preclinical Findings

SynopsisCitrin deficiency (CD) is a genetic metabolic disorder caused by loss of the mitochondrial transporter CITRIN, which plays a role in the urea cycle and malate–aspartate shuttle. Patients wi...

Read more